by Cristy Lytal, University of Southern California Figure 1. Structure-based design of selective CBX8 compounds. (A) Reported CBX7 compounds and their in vitro potency in an AlphaScreen competition assay. (B) Comparison of the alanine binding pocket size of CBX7 (top) and CBX8 (bottom). (C) Comparison of the aromatic cage region of CBX7 (top) and CBX8 (bottom). (D)...
by University of Huddersfield Two different compounds were generated using zinc (left) and manganese (right). Whilst these two compounds “look” very similar, the zinc compound demonstrated excellent anti-cancer activity and selectivity towards a range of cancers in the laboratory, whereas the manganese compound was comparatively much more toxic, meaning there was more anti-cancer activity at a...
by Will Doss, Northwestern University Immunohistochemistry staining showing PD1 expression on tumor cells in a skin biopsy from a cutaneous T-cell lymphoma patient. Credit: Northwestern University Whole-genome sequencing analysis of cutaneous T-cell lymphomas has revealed that deletions of the gene PD1 were associated with worse prognoses, according to a recent Northwestern Medicine study published in Blood. Normally,...
Scientists at the Tokyo Institute of Technology (Tokyo Tech) have designed an eco-friendly protocol for synthesizing gold nanoparticles with optimized morphology for near-infrared light absorption using a biomolecule called B3 peptide. In their paper, they report the synthesis of triangular and circular gold nanoplates and their effectiveness in killing cancer cells by converting the absorbed...
by Ludwig Institute for Cancer Research Credit: CC0 Public Domain A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy. Led by Ludwig Lausanne’s Ping-Chih Ho and Li Tang of the École Polytechnique Fédérale de Lausanne, the study describes how...
The key to a universal cancer therapy is to find a vulnerability that is (a) common to all cancers, something fundamental to cancer as a class, (b) nowhere near as prevalent in normal cells, and (c) can be cost-effectively exploited as a basis for treatment. Lengthening of telomeres is a good example, and an area in which at...
by Walter and Eliza Hall Institute of Medical Research The cell survival protein BCL-XL may protect kidneys from damage caused by cancer therapies. Credit: Art of Science, Dr Michael Roy WEHI researchers have identified a protein that could protect the kidneys from ‘bystander’ damage caused by cancer therapies. The “cell survival protein,” called BCL-XL, was required in...
Penn study shows GPER activation in mice can also make tumors more visible to immune system. Activating the G protein-coupled estrogen receptor (GPER) – a receptor found on the surface of many normal and cancer tissues – has been shown to stop pancreatic cancer from growing, but may also make tumors more visible to the...
by German Cancer Research Center A receptor in the cell layer that lines the blood vessels from the inside stimulates both the formation of new blood vessels in tumors and metastasis. Scientists at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have succeeded in blocking...
A study in mice suggests that by infiltrating tumors and ramping up the body’s immune response, a type of gut bacteria could be a valuable ally in cancer treatment. New research suggests that Bifidobacteria could help fight off tumors. In recent years, research has shown that the communities of bacteria that live in our guts...
